All In Biotech

Drug Trial Radar · NCT06329141

A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients

A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups, Phase 2a Clinical Trial to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients

Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

99

Actual

Start

Jul 22, 2024

Primary completion

Dec 16, 2025

Study completion Jan 7, 2026

Sponsor

Lead sponsor
GlaceumIndustry
Sponsor type
Industry
Collaborators
Kyunghee University Medical Center; Korea University Guro Hospital; Samsung Medical Center; Severance Hospital; Inje University; Hallym University Medical Center; The Catholic University of Korea; Uijeongbu St. Mary Hospital
First posted
Mar 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

1. Study Objective \- To assess the efficacy and safety of vutiglabridin in early Parkindson's disease patients 2. Background Glaceum Inc. has evaluated the safety, tolerability, and pharmacokinetic/pharmacodynamic properties of vutiglabridin in healthy subjects through its Phase 1 trials, and is planning to perform this Phase 2a trial to assess the efficacy and safety of vutiglabridin in early Parkinson's disease patients. 3. Study Design and Protocol This study is a randomized, double-blind, placebo-controlled, parallel-group trial. Subjects deemed eligible to participate in this study based on the inclusion/exclusion criteria will be assigned a subject number and randomized to one of the 3 treatment groups - 1 group receiving a placebo - in a 1:1:1 ratio. Subjects will be randomized to double-blind treatments and will receive a once-daily oral dose of the investigational product for 24 weeks according to the study protocol. Several parameters (i.e., MDS-UPDRS, CGI-C, K-NMSS, modified Hoehn-Yahr stage and SNBR) will be evaluated to assess the efficacy of vutiglabridin. Assessments including measurement of vital signs, 12-lead ECG, clinical laboratory test, pregnancy test, physical examination, and adverse event monitoring will be performed to evaluate the safety and tolerability of vutiglabridin. Blood samples will be collected for pharmacokinetic assessment.

Conditions

  • Parkinson Disease

Interventions

  • VutiglabridinDrug

    Once-daily oral administration

  • PlaceboDrug

    Once-daily oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in MDS-UPDRS Part III SubscoreTime frame: From baseline to Week 24

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Inje University Busan Paik Hospital

    Busan, South Korea

  • Inje University Sanggye Paik Hospital

    Seoul, South Korea

  • KyungHee University Medical Center

    Seoul, South Korea

  • Severance Hospital

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • The Catholic University of Korea

    Seoul, South Korea

  • Korea University Guro Hospital

    Seoul, South Korea

  • Hallym University Medical Center

    Anyang-si, Gyeonggi-do, South Korea

  • The Catholic University of Korea Uijeongbu St.Marys Hostpial

    Uijeongbu-si, Gyeonggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.